|DB00002||Cetuximab||Cetuximab, used in combination with irinotecan, is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy. Cetuximab administered as a single agent is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are intolerant to irinotecan-based chemotherapy.|
|DB00072||Trastuzumab||For treatment of early stage HER2-positive breast cancer, or metastatic breast cancer that substantially overexpress HER2.|
|DB00073||Rituximab||For treatment of CD20-positive non-Hodgkins lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.|
|DB00112||Bevacizumab||As part of combination therapy for metastatic colorectal cancer and HER2-negative metastatic breast cancer.|
|DB05773||Trastuzumab emtansine||Used in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment.
|DB06366||Pertuzumab||Pertuzumab is indicated for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.|
|DB08935||Obinutuzumab||Obinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia.|
|DB09037||Pembrolizumab||Pembrolizumab is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of:
patients with unresectable or metastatic melanoma.
patients with metastatic NSCLC whose tumors have high PD-L1 expression [(Tumor Proportion Score (TPS) ≥50%)] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC.
patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.
patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. |
|DB00056||Gemtuzumab ozogamicin||Indicated for the treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for other cytotoxic chemotherapy. Indicated for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory). |
|DB00110||Palivizumab||For prophylaxis of respiratory diseases casued by respiratory syncytial virus.|
|DB00043||Omalizumab||For treatment of asthma caused by allergies|
|DB00051||Adalimumab||For treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease.|
|DB00065||Infliximab||* Indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult or pediatric (≥ 6 years of age) patients with moderately to severely active **Crohn’s disease** who have had an inadequate response to conventional therapy
* Indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing **Crohn’s disease**.
* Indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult or pediatric (≥ 6 years of age) patients with moderately to severely active **ulcerative colitis** who have had an inadequate response to conventional therapy.
* Indicated for, in combination with methotrexate, reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active **rheumatoid arthritis**.
* Indicated for reducing signs and symptoms in patients with active **ankylosing spondylitis**.
* Indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in patients with **psoriatic arthritis**.
* Indicated for the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) **plaque psoriasis** who are candidates for systemic therapy and when other systemic therapies are medically less appropriate.|
|DB00075||Muromonab||For treatment of organ transplant recipients, prevention of organ rejection|
|DB00087||Alemtuzumab||Alemtuzumab (Campath) is a monoclonal antibody therapy used for treatment of B-cell chronic lymphocytic leukemia.|
|DB00108||Natalizumab||For treatment of multiple sclerosis.|
|DB00111||Daclizumab||Zenapax is a humanized monoclonal antibody used for prevention of renal transplant rejection|
|DB01257||Eculizumab||For the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.|
|DB01270||Ranibizumab||For the treatment of patients with macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.
|DB04949||Pexelizumab||For the treatment of inflammation during cardiac surgery.|
|DB04958||Epratuzumab||Investigated for use/treatment in leukemia (lymphoid), lymphoma (non-hodgkin's), and systemic lupus erythematosus.|
|DB05097||Labetuzumab||Labetuzumab is a humanized monoclonal antibody used to treat cancer. Retrieved from "http://en.wikipedia.org/wiki/Labetuzumab"|
|DB05101||Matuzumab||Investigated for use/treatment in cervical dysplasia/cancer, colorectal cancer, gastric cancer, and lung cancer.|
|DB05111||Fontolizumab||Investigated for use/treatment in crohn's disease and psoriasis and psoriatic disorders.|
|DB05496||Otelixizumab||Investigated for use/treatment in diabetes mellitus type 1, pediatric indications, and psoriasis and psoriatic disorders.|
|DB05555||Enokizumab||Investigated for use/treatment in asthma.|
|DB05595||Farletuzumab||Investigated for use/treatment in ovarian cancer.|
|DB05656||Veltuzumab||Investigated for use/treatment in lymphoma (non-hodgkin's).|
|DB05679||Ustekinumab||Ustekinumab is indicated for management of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy; or is used alone or in conjunction with methotrexate for the management of active psoriatic arthritis in adults. The FDA approved the use of ustekinumab in September 2016 for the treatment of moderate to severe Crohn's disease. The use of ustekinumab may improve short term clinical response but not clinical remission in moderate to severe Crohn's disease.|
|DB05797||TNX-901||Investigated for use/treatment in allergic reaction.|
|DB05889||Inotuzumab ozogamicin||Indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). |
|DB05892||RI 624||Investigated for use/treatment in pain (acute or chronic).|
|DB06116||Eldelumab||Investigated for use/treatment in ulcerative colitis.|
|DB06192||Nimotuzumab||Investigated for use/treatment in head and neck cancer, brain cancer, pediatric indications, pancreatic cancer, lung cancer, and colorectal cancer.|
|DB06273||Tocilizumab||Indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). It is also indicated for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) and active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and older.|
|DB06310||Motavizumab||Investigated for use/treatment in viral infection and pediatric indications.|
|DB06317||Elotuzumab||Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.|
|DB06342||Coltuximab ravtansine||Investigated for use/treatment in lymphoma (non-hodgkin's).|
|DB06360||Lucatumumab||Investigated for use/treatment in leukemia (lymphoid), multiple myeloma, and lymphoma (unspecified).|
|DB06371||Siplizumab||Investigated for use/treatment in psoriasis and psoriatic disorders, transplant (rejection), graft versus host disease, lymphoma (unspecified), and leukemia (unspecified).|
|DB06467||Apolizumab||Investigated for use/treatment in lymphoma (non-hodgkin's), leukemia (lymphoid), and solid tumors.|
|DB06550||Bivatuzumab||Investigated for use/treatment in cancer/tumors (unspecified) and head and neck cancer.|
|DB06602||Reslizumab||Indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype.|
|DB06606||Teplizumab||Investigated for use/treatment in diabetes mellitus type 1.|
|DB06612||Mepolizumab||Mepolizumab is indicated for add-on maintenance treatment of severe eosinophilic asthma, as identified by blood eosinophils greater than or equal to 150 cells/μl at initiation of treatment or blood eosinophils greater than or equal to 300 cells/μl in the past 12 months, in patients aged 12 years and older. Mepolizumab has been shown to reduce exacerbations of asthma in patients with an exacerbation history|
|DB06643||Denosumab||Prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It reduces the incidence of vertebral, nonvertebral, and hip fractures. Prolia is also indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. It can also be used in men with osteoporosis at high risk for fracture or in men receiving androgen deprivation therapy for nonmetastatic prostate cancer to increase bone mass. Xgeva is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumors.|
|DB08879||Belimumab||Adjunct treatment for auto-antibody-positive active systemic lupus erythematosus. |
|DB08904||Certolizumab pegol||Reducing signs and symptoms of Crohn's disease and treatment of moderately to severely active rheumatoid arthritis (RA). |
|DB09033||Vedolizumab||Vedolizumab is indicated for adult patients with moderately to severely active UC or CD who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids. |
|DB09264||Idarucizumab||For use in patients treated with Dabigatran when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding.|
|DB11569||Ixekizumab|| Ixekizumab is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. |
|DB11767||Sarilumab||Indicated for modere to severe reactive RA in adult patients who are irresponsive, respond inadequately or present intolerance to disease-modifying anti-rheumatic drugs (DMARDs) or tumor necrosis factor (TNF) antagonists. It is indicated to be used in combination with methotrexate (MTX) or as a monotherapy when there is intolerance to MTX or MTX administration is inappropriate.|
|DB11988||Ocrelizumab||Indicated for the treatment of adult patients with relapsing or primary progressive forms of multiple sclerosis [FDA Label].|
|DB12489||Mirvetuximab Soravtansine||Not Available|
|DB12589||Dacetuzumab||Investigated for use/treatment in lymphoma (non-hodgkin's) and multiple myeloma.|
|DB12893||Sacituzumab govitecan||Not Available|
|DB13923||Emicizumab||The main function of Emicizumab is the prevention of bleeding episodes. Thus, Emicizumab is approved for the routine prophylaxis of patients with hemophilia A that present Factor VIII inhibitors. Hemophilia A is a deficiency of coagulation Factor VIII which causes a serious bleeding disorder. The standard treatment is done with the administration of recombinant or serum-deriver Factor VIII which induces the formation of anti-factor VIII alloantibodies (Factor VIII inhibitors) and renders the standard treatment ineffective.[A31286]|
|DB01269||Panitumumab||For the treatment of EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.|
|DB05578||Ramucirumab||For use in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy.|
|DB06186||Ipilimumab||Ipilimumab is indicated for the treatment of unresectable or metastatic melanoma in adults. It is also used to reduce the risk of the deadly skin cancer returning after surgery.|
|DB06607||Catumaxomab||For use in the management of malignant ascites tumours via intraperitoneal infusion where standard therapy is not available or feasible [FDA Label].|
|DB06650||Ofatumumab||Ofatumumab is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab.|
|DB08870||Brentuximab vedotin||Used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma.|
|DB09035||Nivolumab||Nivolumab is indicated for the treatment of unresectable or metastatic melanoma for patients who no longer respond to treatment with other drugs. It is intended for use in patients who have been previously treated with ipilimumab and is used for melanoma patients after treatment with ipilimumab and a BRAF inhibitor in patients whose tumors express BRAF V600 gene mutations. Historically there have been very few effective treatments for advanced melanoma, which is why this product was approved under an FDA accelerated program to allow earlier patient access.|
|DB09052||Blinatumomab||Indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).|
|DB09077||Dinutuximab||Dinutuximab is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.|
|DB09559||Necitumumab||Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). It is not indicated for treatment of non-squamous NSCLC. |